Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Expert Rev Cardiovasc Ther ; 13(8): 915-22, 2015.
Article in English | MEDLINE | ID: mdl-26163051

ABSTRACT

A systematic search of Medline, EMBASE and CINAHL electronic databases was performed. Original research articles reporting all-cause mortality following surgery in patients with aortic regurgitation and severe left ventricular systolic dysfunction (LVSD) were identified. Nine of the 10 eligible studies were observational, single-center, retrospective analyses. Survival ranged from 86 to 100% at 30 days; 81 to 100% at 1 year and 68 to 84% at 5 years. Three studies described an improvement in mean left ventricular ejection fraction (LVEF) following aortic valve replacement (AVR) of 5-14%; a fourth study reported an increase in mean left ventricular ejection fraction (LVEF) of 9% in patients undergoing isolated AVR but not when AVR was combined with coronary artery bypass graft and/or mitral valve surgery. Three studies demonstrated improvements in functional New York Heart Association (NYHA) class following AVR. Additional studies are needed to clarify the benefits of AVR in patients with more extreme degrees of left ventricular systolic dysfunction (LVSD) and the potential roles of cardiac transplantation and transaortic valve implantation.


Subject(s)
Aortic Valve Insufficiency/therapy , Ventricular Dysfunction, Left/therapy , Aortic Valve Insufficiency/complications , Humans , Retrospective Studies , Ventricular Dysfunction, Left/complications
2.
Circ Heart Fail ; 8(4): 717-24, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26067854

ABSTRACT

BACKGROUND: The aim of our study was to investigate the relationship between coronary artery disease (CAD), angina, and clinical outcomes in patients with heart failure and preserved ejection fraction enrolled in the irbesartan in patients with heart failure and preserved systolic function (I-Preserve) trial. METHODS AND RESULTS: The mean follow-up period for the 4128 patients enrolled in I-Preserve was 49.5 months. Patients were divided into 4 mutually exclusive groups according to history of CAD and angina: patients with no history of CAD or angina (n=2008), patients with no history of CAD but a history of angina (n=649), patients with a history of CAD but no angina (n=468), and patients with a history of CAD and angina (n=1003); patients with no known CAD or angina were the reference group. After adjustment for other prognostic variables using Cox proportional-hazard models, patients with CAD but no angina were found to be at higher risk of all-cause mortality (hazard ratio [HR], 1.58 [1.22-2.04]; P<0.01) and sudden death (HR, 2.12 [1.33-3.39]; P<0.01), compared with patients with no CAD or angina. Patients with CAD and angina were also at higher risk of all-cause mortality (HR, 1.29 [1.05-1.59]; P=0.02) and sudden death (HR, 1.83 [1.24-2.69]; P<0.01) compared with the same reference group and had the highest risk of unstable angina or myocardial infarction (HR, 5.84 [3.43-9.95]; P<0.01). CONCLUSIONS: Patients with heart failure and preserved ejection fraction and CAD are at higher risk of all-cause mortality and sudden death when compared with those without CAD. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00095238.


Subject(s)
Angina Pectoris/mortality , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Biphenyl Compounds/therapeutic use , Coronary Artery Disease/mortality , Death, Sudden, Cardiac/epidemiology , Heart Failure/drug therapy , Heart Failure/mortality , Systole , Tetrazoles/therapeutic use , Ventricular Function, Left , Aged , Angina Pectoris/diagnosis , Angina Pectoris/physiopathology , Angiotensin II Type 1 Receptor Blockers/adverse effects , Biphenyl Compounds/adverse effects , Coronary Artery Disease/diagnosis , Coronary Artery Disease/physiopathology , Female , Heart Failure/diagnosis , Heart Failure/physiopathology , Humans , Irbesartan , Kaplan-Meier Estimate , Male , Middle Aged , Proportional Hazards Models , Randomized Controlled Trials as Topic , Retrospective Studies , Risk Assessment , Risk Factors , Stroke Volume , Tetrazoles/adverse effects , Time Factors , Treatment Outcome
3.
Eur J Heart Fail ; 17(2): 196-204, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25678097

ABSTRACT

AIMS: To investigate the relationship between angina pectoris and fatal and non-fatal clinical outcomes in heart failure with reduced and preserved ejection fraction (HF-REF and HF-PEF, respectively). METHODS AND RESULTS: Of 7599 patients in the CHARM program, 5408 had ischaemic heart disease; 3855 had HF-REF (ejection fraction ≤45%) and 1553 had HF-PEF. These patients were separated into three groups: no history of angina, previous angina, and current angina. Three coronary outcomes were examined: fatal or non-fatal myocardial infarction (MI); MI or hospitalization for unstable angina (UA); and MI, UA or coronary revascularization. The composite heart failure outcome of cardiovascular death or heart failure hospitalization (HFH) was also analysed, along with its components and all-cause mortality. New York Heart Association functional class was worse in both HF-REF and HF-PEF patients with current angina compared with patients without angina (P < 0.001 and P = 0.005 respectively), despite similar clinical examination findings and ejection fraction. Patients with current angina had a higher risk of all three coronary outcomes (adjusted hazard ratios ranging from 1.8-3.1) than those without angina but did not have a higher risk of heart failure outcomes or all-cause mortality. CONCLUSION: In patients with heart failure current angina is associated with significantly more functional limitation and a higher risk of coronary events, across the spectrum of left ventricular ejection fraction.


Subject(s)
Angina Pectoris/physiopathology , Benzimidazoles/therapeutic use , Heart Failure/physiopathology , Myocardial Infarction/physiopathology , Myocardial Revascularization , Tetrazoles/therapeutic use , Aged , Angina Pectoris/diagnosis , Angina Pectoris/mortality , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Biphenyl Compounds , Comorbidity , Female , Heart Failure/diagnosis , Heart Failure/mortality , Humans , Male , Middle Aged , Myocardial Infarction/diagnosis , Myocardial Infarction/mortality , Patient Outcome Assessment , Stroke Volume/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...